Amgen reports AimovigTM (erenumab) met all primary and secondary endpoints
Amgen announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of AimovigTM (erenumab) 140 mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects. January 22, 2018